Last Updated:
From Semaglip, Sematop, Semakind to Semastrike, Semaglyn and Semaril, the pipeline of upcoming Ozempic copycats reads like variations of the semaglutide molecule itself
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. File pic/Reuters
If there is one prefix that is likely to dominate prescriptions in India over the coming months, it may well be “Sema”.
With key patents around semaglutide—the blockbuster molecule behind drugs like Ozempic and Wegovy—set to expire in India next week, Indian pharmaceutical companies are ready to introduce their own versions. Industry insiders say more than 50 brands are preparing for launch, and a curious pattern is emerging: most of them begin with the same four letters.
From Semaglip, Sematop, Semakind, Semester, Semaglide, and Semalup to Semastrike, Semaglyn, Semaril, Semapride, Semalup, and Semalix, the pipeline of upcoming copycat versions of Ozempic reads almost like variations on the original molecule—semaglutide. In fact, industry estimates suggest around 80–85 per cent of brands preparing for launch start with “Sema”, reflecting how companies anchor their brand names directly to semaglutide. While many companies have chosen “Sema” as a prefix, others have flipped the formula—turning it into a suffix. Brand names such as Trusema, Glusema, Obesema, and Zepsema reflect another variation of the same naming strategy built around the molecule.
The naming trend underscores the scale of competition expected once generics enter the market. With at least 54 companies ready with brand names. Developed by Novo Nordisk, the molecule has been on the market for close to a decade and has accumulated tens of millions of patient-years of exposure worldwide, making it one of the most widely used GLP-1 therapies. The patent is expected to expire on March 21.
Globally, semaglutide—marketed as Ozempic and Wegovy—has reshaped the obesity treatment landscape, with the drug gaining widespread attention after celebrities and influencers began openly discussing the use of GLP-1 medicines for weight loss.
For Indian drugmakers, the patent expiry represents both an opportunity and a technical challenge. Unlike conventional tablets, semaglutide is a complex peptide therapy, often delivered through injectable pens, which requires advanced manufacturing capabilities and stringent quality controls. Companies and endocrinologists both told News18 that while several players may enter the market, differentiation will depend on formulation quality, delivery devices, and supply capacity.
With the increasing competition, prices are set to be halved, according to the majority of estimates. Systematix Institutional Equities, in its report on “generic semaglutide”, expects the adoption of GLP-1 therapy among diabetics to rise sharply following the launch of the generic semaglutide version, driven by an affordable price point—potentially 30% to 50% lower than the current level. “Over time, prices could further correct as low as 70%-75% from current levels.” Currently, an Ozempic 1 mg injection costs Rs 11,135 for a monthly dose, which is expected to cost between Rs 5,000 and Rs 8,000 after patent expiry. After a few months, as per estimates, the cost may sink to around Rs 2,500 per week.
Here, conservative estimates peg it around a 30% price fall, at least. “With Semaglutide loss of exclusivity, prices are expected to soften. Even a 20-30% lower price could be enough to meaningfully lower the affordability barrier, potentially bringing GLP-1 therapies within reach for many more patients,” said Gauri Pathak, head of Ipsos Healthcare, India.
A repeat of the sitagliptin playbook
The rush is also drawing comparisons with previous blockbuster diabetes drugs that saw a similar surge of competing brands. Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists (AIOCD), said the market had witnessed a comparable scramble when sitagliptin lost exclusivity and multiple Indian companies launched their own versions. According to him, a similar competitive wave is now expected with semaglutide, with companies across the spectrum—from smaller firms to large pharmaceutical players—preparing to capture market share. At the same time, he said the association has advised its members “not to dispense the drug without a doctor’s prescription in the interest of public safety”.
Doctors say the wider availability could also improve access. “A wise physician will use a proper and standard brand. Surely, healthcare professionals will have more flexibility to start these drugs in the economically weaker section of people. Wider availability will also be important,” said Anoop Misra, chairman, Fortis C-DOC Hospital for Diabetes and Allied Sciences, New Delhi.
Pharma firms gear up for the ‘Sema’ race
Pharmaceutical firms preparing to enter the market say the bigger impact could be on access. Several pharmaceutical companies, including Alkem, Mankind, Ajanta Pharma, Zydus Healthcare, Macleods Pharmaceuticals, Micro Labs, Glenmark, Lupin, Sun Pharma, Emcure Pharmaceuticals, Akums, Dr Reddy’s, Torrent, Cipla, and Alembic, among others, are part of the race.
As prices fall with generic competition, doctors may be able to prescribe the therapy to a far larger pool of patients struggling with diabetes and obesity.
Samit Mehta, whole-time director at Emcure Pharmaceuticals, says the growing availability of treatments targeting obesity is important given the scale of the problem. “Obesity is among the most significant public health challenges of our time, and more solutions to help combat this disease are a good thing for patients,” he said, noting that semaglutide has already seen widespread global use with millions of patient-years of exposure across its products.
Several companies told News18 they are preparing to launch their versions immediately after the patent expiry. Kirti Ganorkar, managing director of Sun Pharma, said the company plans to be present from “day one of the generic rollout” and intends to offer semaglutide across both major indications—chronic weight management and type-2 diabetes. The company’s products will be offered in pre-filled pen formats, he said, adding that the focus will be on ensuring adequate supply once demand expands.
Other firms are also betting on the therapy’s potential in tackling metabolic diseases in India. Vijay Charlu, president of domestic business at CORONA Remedies, described semaglutide as a significant advancement in managing metabolic disorders and said the company is preparing to introduce the therapy through “a strategic partnership model immediately after patent expiry” with an emphasis on improving access to high-quality treatment options.
At the same time, manufacturers caution that producing semaglutide is far more complex than manufacturing traditional generics. Saurabh Agarwal, director at HAB Pharmaceutical and Research, said peptide drugs involve complex synthetic chemistry and stringent impurity controls, while injectable pens are regulated as drug-device combinations. As multiple companies enter the market, he said, quality differentiation will become important even as competition improves affordability and expands access in India and export markets.
Indian pharma landscape revamp possible
Market analysts believe the category could reshape India’s pharmaceutical landscape over the next few years. Vishal Manchandna, pharma analyst at Systematix, said the patent expiry is expected to significantly expand access to GLP-1 therapies and improve affordability, enabling doctors to treat conditions that are currently under-treated.
However, he noted that because semaglutide is a peptide therapy delivered through specialised devices, it may still remain relatively expensive compared with other chronic treatments. “In line with global trends, analysts expect diabetes treatment to account for the bulk of prescriptions, with use for non-diabetic obesity likely to remain smaller initially.”
Even so, the broader impact could be significant. Manchandna expects the GLP-1 segment to emerge as one of the largest growth drivers in the Indian pharmaceutical market, potentially accelerating overall industry growth over the next three to four years.
March 06, 2026, 07:30 IST